Role of the Peritoneal Microenvironment in the Pathogenesis and Spread of Colorectal Carcinomatosis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03777943

Acronym

MMT

Enrollment

Registered

2018-12-19

Start date

2017-11-01

Completion date

2022-03-28

Last updated

2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peritoneal Carcinomatosis

Brief summary

The goal of this project is to investigate the extent and role of mesothelial - mesenchymal transition (MMT) and cancer associated fibroblasts (CAFs) in the pathogenesis of colorectal peritoneal carcinomatosis (PC).

Interventions

PROCEDURESampling peritoneal tissue

Resection specimen will be obtained during CRS from normal peritoneum at a distance, normal peritoneum close to a peritoneal metastasis, miliary peritoneal carcinomatosis, and established peritoneal carcinomatosis.

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

• Patients presenting with colorectal peritoneal carcinomatosis

Exclusion criteria

* Pregnancy or breast feeding * Psychiatric pathology capable of affecting comprehension and judgment faculty * HIPEC (hyperthermic intraperitoneal chemotherapy) or PIPAC (pressurized intraperitoneal aerosol chemotherapy) in the past * Abdominal radiation treatment

Design outcomes

Primary

Measure	Time frame	Description
Immunohistochemistry (IHC) analysis	Within 6 months after collection of the samples	Extensive IHC analysis will be performed including CD44, integrins, ICAM-1, hyaluronate, and VCAM-1 (adhesion molecules); calretinin, mesothelin, WT1, cytokeratins and E-cadherin (mesothelial markers); α-SMA, FAP and podoplanin (CAF specific markers); PDGF, VEGF and EDGF (angiogenesis related markers)

Secondary

Measure	Time frame	Description
Intra-tumoral versus peritoneal vascularity	Within 6 months after collection of the samples	Vacularity will be assed using chalkley counts
Laser capture microdisssection (LCM) followed by gene expression analysis	Within 12 months after collection of the samples	Different cell types (mesothelial cells, submesothelial resident fibroblasts, CAFs) will be isolated using LCM, followed by gene expression analysis

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026